Reading this on a mobile device? Try our optimized mobile version here:

March 1, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Public health, medical research to suffer from sequestration
    Sequestration will hit hard in public health and medical research, both of which have been restricted by years of underfunding or retrenchment. "These cuts are going to have a real impact," Washington state Health Secretary Mary Selecky said. "In the next six to eight weeks, we're going to have to say we're closed on Fridays or we can't provide this or that service anymore." Researchers who depend on NIH grants have also expressed concern that their work will have to be scaled back. Los Angeles Times (tiered subscription model) (2/27) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Draft on electronic submissions raises concerns for BIO
    Draft guidelines from the FDA on the electronic submission of data from clinical sites don't ensure that industry can rely on technical specifications to allow long-term planning, BIO said. The guidelines should address duplicative submissions that can delay site inspections, Pharmaceutical Research and Manufacturers of America said. (2/28) LinkedInFacebookTwitterEmail this Story
  • Baxter submits hemophilia drug for FDA approval
    Baxter International filed a biologics license application with the FDA for approval to use FEIBA NF Nanofiltered and Vapor Heated, its anti-inhibitor coagulant complex treatment, in patients with hemophilia A or B and inhibitors. The application was based on a late-stage trial that found routine prophylactic treatment was associated with a 72.5% decrease in bleeding rates. Pharmaceutical Business Review Online (2/28) LinkedInFacebookTwitterEmail this Story
  • Roche agrees to release clinical trial studies
    Swiss pharmaceutical firm Roche Holding has agreed to establish a procedure for releasing data from its clinical trials, including its highly successful flu medicine, Tamiflu. The company will use a process that enables access to trial data without compromising patient confidentiality or publishing misleading results, according to pharmaceuticals unit head Daniel O'Day. Earlier, British-owned GlaxoSmithKline agreed to publish its own clinical study reports and trial results. Reuters (2/27) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  • Secure site for biotech crop trials created in Switzerland
    The Swiss government plans to establish a protected site for biotech crop trials to allow research without fear of vandalism. The site at the Reckenholz research station near Zurich will first be used for a wheat test. Lawmakers believe trials "should be protected and that the research agenda should not be determined by vandals," said Reckenholz senior researcher Michael Winzeler. (2/28) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • DuPont Pioneer exec hopeful cellulosic sector will meet RFS goals
    The U.S. produced 20,000 gallons of cellulosic biofuels last year and is projected to produce 250 million gallons in 2015, short of the Renewable Fuel Standard's 2012 target of 500 million gallons and one billion gallons this year. But Andy Heggenstaller, agronomy research manager for DuPont Pioneer, is optimistic that the industry will rise to the challenge. "I think what we're going to see is that DuPont and some other companies are going to make this happen in that 2015 timeframe," Heggenstaller said. Brownfield (2/28), The Hartford Courant (Conn.) (2/26) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Mediocrity knows nothing higher than itself, but talent instantly recognizes genius."
--Sir Arthur Conan Doyle,
Scottish-born writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information